167097-00-9

Usage

Uses

Used in Pharmaceutical Industry:
Trans-3,4-Dihydroxypiperidine-1-carboxylic acid benzyl ester is used as a key intermediate in the synthesis of drugs and pharmaceuticals for its potential role in the development of new medications. Its unique structure and properties make it a valuable component in the creation of therapeutic agents for various diseases.
Used in Drug Synthesis:
In the field of drug synthesis, trans-3,4-Dihydroxypiperidine-1-carboxylic acid benzyl ester is used as a precursor for the development of novel compounds with potential therapeutic applications. Its presence in the molecular structure can influence the pharmacokinetics and pharmacodynamics of the resulting drugs, making it an essential component in medicinal chemistry.
Used in Organic Synthesis Research:
trans-3,4-Dihydroxypiperidine-1-carboxylic acid benzyl ester is also used as a building block in organic synthesis research, where its reactivity and structural features are explored to create new organic molecules with specific properties and functions. Its utility in this field underscores its importance in advancing chemical knowledge and innovation.
Used in Neurological and Cardiovascular Drug Development:
Specifically, in the development of drugs for neurological and cardiovascular diseases, trans-3,4-Dihydroxypiperidine-1-carboxylic acid benzyl ester is employed as a structural element in the design of new pharmaceutical agents. Its incorporation into these drugs aims to address unmet medical needs and improve patient outcomes in these therapeutic areas.

InChI:InChI=1/C13H17NO4/c15-11-6-7-14(8-12(11)16)13(17)18-9-10-4-2-1-3-5-10/h1-5,11-12,15-16H,6-9H2/t11-,12-/m0/s1

Upstream product

• 66207-23-6 1-benzyloxycarbonyl-1,2,3,6-tetrahydropyridine 
• 501-53-1 benzyl chloroformate 
• 694-05-3 1,2,3,6-tetrahydropyridine 
• 66207-08-7 3,4-epoxy-piperidine-1-carboxylic acid benzyl ester 
• 1624258-63-4 rac-benzyl 7-oxa-3-azabicyclo[4.1.0]heptane-3-carboxylate 
• 37088-07-6 1,4,5-trideoxy-1,5-imino-D-threo-pentitol 
• 266688-37-3 methyl 4-cyano-4-deoxy-D-threonate 
• 266688-40-8 5-amino-4,5-dideoxy-D-threo-pentono-1,5-lactam 
• 886847-37-6 (3R,4R)-3-acetoxy-1-benzyloxycarbonyl-4-hydroxypiperidine 
• 443648-89-3 (-)-(3R,4R)-3,4-dihydroxypiperidine hydrochloride 
• 108-05-4 vinyl acetate 
• 167096-99-3 (+/-)-trans-1-benzyloxycarbonyl-3,4-dihydroxypiperidine 
• 266688-38-4 methyl 2,3-di-O-acetyl-4-cyano-4-deoxy-D-threonate 
• 266688-39-5 5-amino-2,3-di-O-acetyl-4,5-dideoxy-D-threo-pentono-1,5-lactam 

Downstream Products

• 37088-07-6 1,4,5-trideoxy-1,5-imino-D-threo-pentitol 
• 37088-07-6 (3S,4R)-piperidine-3,4-diol 
• 1247884-87-2 3,4-diazidopiperidine-1-carboxylic acid benzyl ester 
• 1247884-89-4 benzyl 3,4-diaminopiperidine-1-carboxylate 

Relevant academic research and scientific papers

BETA-LACTAMASE INHIBITORS

Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.

BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS

The invention relates to bicyclic compounds of formulas I and I', and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.

Glycosynthase-Mediated Assembly of Xylanase Substrates and Inhibitors

An exo-β-xylosidase mutant with glycosynthase activity was created to aid in the synthesis of xylanase substrates and inhibitors. Simple monosaccharides were easily elaborated into di-, tri- and tetrasaccharides by using this enzyme. Some products proved

Bicyclic carbamates as inhibitors of papain-like cathepsin proteases

A 6-oxa-1-aza-bicyclo[3.2.1]octan-7-one system inhibits the proteolytic activity of several cysteine proteases belonging to the papain family. In vitro mechanistic studies and in silico calculations suggest that the minimal π-overlap between the bridgehea

Biocatalytic preparation of enantioenriched 3,4-dihydroxypiperidines and theoretical study of Candida antarctica lipase B enantioselectivity

Enzymatic acetylations of N-substituted cis- and trans-3,4- dihydroxypiperidine and hydrolysis of their diacetylated derivatives have been studied. High enantioselectivities are obtained with Pseudomonas cepacia lipase and Candida antarctica lipase B for

MODULATORS OF CELLULAR ADHESION

The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).

CHEMOKINE RECEPTOR ANTAGONISTS

A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof, wherein the variants R, R9, Z, X, Q and Y are defined in the specification.

Enantioselective Trans Dihydroxylation of Nonactivated C-C Double Bonds of Aliphatic Heterocycles with Sphingomonas sp. HXN-200

The bacterial strain Sphingomonas sp. HXN-200 was used to catalyze the trans dihydroxylation of N-substituted 1,2,5,6-tetrahydropyridines 1 and 3-pyrrolines 4 giving the corresponding 3,4-dihydroxypiperidines 3 and 3,4-dihydroxypyrrolidines 6, respectivel

Stereoelectronic substituent effects in polyhydroxylated piperidines and hexahydropyridazines

From the pKa values of the conjugate acids of a large series of hydroxylated piperidines and hexahydropyridazines, a consistent difference in basicity was found between stereo-isomers having an axial or equatorial hydroxyl (OH) group either β o

Nanomolar versus millimolar inhibition by xylobiose-derived azasugars: Significant differences between two structurally distinct xylanases

The synthesis of xylobiose-derived nitrogen-containing inhibitors of xylanase is described starting with accessible precursors through efficient synthetic schemes. Four disaccharides were identified as powerful competitive inhibitors of the retaining fami